



ADULT MEDICATION GUIDELINE					
Alteplase					
Scope (Staff):	All WNHS Staff				
Scope (Area):	Obstetrics and Gynaecology				
This document should be read in conjunction with the Disclaimer.					

# **Quick Links**

DoseAdministrationMonitoringPregnancy and Breastfeeding

### Restrictions

**Formulary: Restricted** 

HIGH RISK Medication \_\_\_\_\_

# Medication Class

Thrombolytic

### **Presentation**

Vial (powder for reconstitution with diluent): 50mg with 50mL diluent

# Storage

Store below 30°C

#### Dose

Refer to FSH Alteplase Specialised Drug Administration Guideline

NB: KEMH and SCGH only stock alteplase; regarding Section 1.6 of the FSH guideline (Pulmonary Embolism), please use the recommended alteplase dose as there is no data to suggest tenecteplase is associated with better outcomes than alteplase

### **Administration**

Refer to FSH Alteplase Specialised Drug Administration Guideline

# **Monitoring**

Monitor vital signs and ECG before use

### **Pregnancy**

1st Trimester: Considered safe to use
 2nd Trimester: Considered safe to use
 3rd Trimester: Considered safe to use

### **Breastfeeding**

Considered safe to use

## Related Policies, Procedures & Guidelines

FSH Alteplase Specialised Drug Administration Guideline

#### References

Australian Medicines Handbook. Alteplase. In: Australian Medicines Handbook [Internet]. Adelaide (South Australia): Australian Medicines Handbook; 2022 [cited 2022 Mar 10]. Available from: https://amhonline.amh.net.au/

MIMS Australia. Alteplase. In: MIMS Online [Internet]. St Leonards (New South Wales): MIMS Australia; 2020 [cited 2022 March 10]. Available from: https://www.mimsonline.com.au

The Royal Women's Hospital. Alteplase. In: Pregnancy and Breastfeeding Medicines Guide [Internet]. Parkville (Victoria): The Royal Women's Hospital; 2022 [cited 2022 Mar 10]. Available from: https://thewomenspbmg.org.au/

Keywords	Alteplase, Actilyse, thrombolytic, rt-PA, recombinant tissue plasminogen activator, STEMI, myocardial infarction, MI, ischaemic stroke, thrombosis, pulmonary embolism, PE, peripheral arterial thrombosis, mechanical valve thrombolysis, venous thromboembolism, VTE							
Record Number:	F/20/3816							
Document Owner:	Chief Pharmacist							
Author/ Reviewer	KEMH Pharmacy Department							
Version Info:	2.0							
Date First Issued:	04/2018	Last Reviewed:	11/03/2022		Review Date:	11/03/2025		
Endorsed by:	Medicines and T	herapeutics Comm		Date:	13/04/2022			
NSQHS Standards Applicable:	Std 1: Clinical Governance			Std 5: Comprehensive Care				
	Std 2: Partnering with Consumers			Std 6: Communicating for Safety				
	Std 3: Phealthcare Asso	reventing and Cont ciated Infection	Std 7: Blood Management					
	Std 4: Medication Safety			Std 8: Recognising and Responding to Acute Deterioration				
Printed or personally saved electronic copies of this document are considered uncontrolled.  Access the current version from WNHS HealthPoint.								

The health impact upon Aboriginal people has been considered, and where relevant incorporated and appropriately addressed in the development of this document (insert ISD Number). (Please refer to the Aboriginal Health Impact Statement and Declaration for Department of Health and Health Service Provider Guidelines – please delete once you have completed this).

This document can be made available in alternative formats on request for a person with a disability.

### © Women and Newborn Health Service 2022

Copyright of this material is vested in the State of Western Australia unless otherwise indicated. Apart from any fair dealing for the purposes of private study, research, criticism or review, as permitted under the provisions of the Copyright Act 1968, no part may be reproduced or re-used for any purposes whatsoever without written permission of the State of Western Australia.